{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-19219409-exenatide:v1","objectPathId":"pubmed-pmid-19219409-exenatide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-19219409-exenatide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19219409-exenatide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19219409-exenatide-v1.md"},"story":{"slug":"pubmed-pmid-19219409-exenatide","version":1,"domain":"Literature metadata","dateInSource":"2026-01-28","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["exenatide"],"peptides":[{"slug":"exenatide","url":"https://peptidescanner.com/peptides/exenatide/"}]},"claims":[{"id":"headline","text":"Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.","sourceIds":["pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8"]},{"id":"summary","text":"PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8"]},{"id":"paragraph-1","text":"PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8"]}],"sources":[{"id":"pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8","name":"PubMed","sourceClass":"A","title":"Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. · retained source version 1:2026-01-28:current:629863bb85d8032a9c1436928a15ec9f6730c0928d8fc669a8525b2be0a76df2","url":"https://pubmed.ncbi.nlm.nih.gov/19219409/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"0c73ea3e8aa6217ef209d156e9dd478db9f3fa561f1dcccb99fbcad5cb2a60ff","tierARecordSha256":"a5e86b59e820272b0a0e6938ffbdb45112b174942c13b29aeb7a56ad2964d01e"},"integrity":{"algorithm":"sha256","contentSha256":"623902d569767b42ae1754bb4ea663abf7d1404b796e8dd5223470964793b6c2"}}